Doruk Erkan, MD

Dr. Doruk Erkan is an Associate Physician-Scientist at the Barbara Volcker Center for Women and Rheumatic Diseases, Associate Attending Rheumatologist and Clinical Researcher at Hospital for Special Surgery, and Associate Professor of Medicine at Weill Cornell Medical College.

In addition to his rheumatology practice, Dr. Erkan has a long-standing research interest in Antiphospholipid Syndrome (an autoimmune clotting disorder) and Systemic Lupus Erythematosus (SLE or “lupus”). After his Internal Medicine residency at Beth Israel Medical Center in New York, he completed his Rheumatology fellowship at Hospital for Special Surgery in New York. Dr. Erkan has a medical doctor (MD) degree from Hacettepe University School of Medicine in Ankara, Turkey and a master of public health (MPH) degree from Johns Hopkins University School of Public Health in Baltimore, Maryland.

Dr. Erkan has received several honors and awards from the American College of Rheumatology and the Arthritis Foundation for his research. He has published over 100 articles including research papers and invited editorials, as well as over 20 book chapters, and he has given over 100 research presentations and 80 invited lectures. He is the co-editor of the Neurology volume of the Handbook of Systemic Autoimmune Disease and the Associate Editor of Hospital for Special Surgery’s Manual of Rheumatology and Outpatient Orthopedic Disorders.

Appointments

Associate Attending Rheumatologist, Hospital for Special Surgery
Associate Professor of Medicine, Weill Cornell Medical College
Associate Physician-Scientist, Barbara Volcker Center for Women and Rheumatic Disease
Clinical Co-Director, Mary Kirkland Center for Lupus Care

Specialty

Rheumatology

Special Expertise

Antiphospholipid syndrome (APS)
Systemic lupus erythematosus (SLE)
APS and SLE Pregnancy
Medical multimedia for physician and patient education

Awards

Lupus Research Award, New York Community Trust, 2008
Rudd-Gardy Teaching Excellence Award, HSS Division of Rheumatology, 2008
Young Investigator Award, AESKU.KIPP Institute, Germany, 2007
Young Investigator Initiative Award, US Bone and Joint Decade, 2006
Antiphospholipid Syndrome Research Award, New York Community Trust, 2004
Dorothy W. Goldstein Young Scholar Award, Arthritis Foundation, New York Chapter, 2002
Rheumatology Fellow Award, American College of Rheumatology, 2001
Postdoctoral Fellowship Award, Arthritis Foundation, New York Chapter, 2001

Affiliations

American College of Rheumatology, Fellow
New York Rheumatism Association, Executive Committee
APS ACTION, Executive Committee Chair

Specialized Centers

• Mary Kirkland Center for Lupus Care
  
• Barbara Volcker Center for Women and Rheumatic Diseases
  
• APS ACTION
  

Education

Medical Doctor (MD), Hacettepe University School of Medicine, Ankara, Turkey
Master of Public Health (MPH), Johns Hopkins University School of Public Health, Baltimore, Maryland

Residency

Internal Medicine, Beth Israel Medical Center, New York

Fellowship

Rheumatology, Hospital for Special Surgery, New York

Certification

American Board of Rheumatology, 2001, 2011
American Board of Internal Medicine, 1999, 2009
Certificate in Clinical Epidemiology and Health Services Research, Weill Cornell Medical College, 2000

State Licensure

New York  

Doruk Erkan, MD has contributed to the following articles on HSS.edu:

Selected Publications

Top 10 Series for Patients

• Antiphospholipid Syndrome Terminology
• Surgical Procedures in Antiphospholipid Antibody-Positive Patients
• APS ACTION International Clinical Database and Repository
• Catastrophic Antiphospholipid Syndrome
• Prevention of Blood Clots in Antiphospholipid Antibody-Positive Patients
• Lupus and Gender
• Lupus and Cardiovascular Disease
• Lupus and Pregnancy

Google Scholar Listing

Books:

• Erkan D, Levine SR (Volume Editors). Handbook of Systemic Autoimmune Diseases, Volume 3: Neurologic Involvement in Systemic Autoimmune Diseases. Elsevier Science, 2004.
• Erkan D, Pierangeli SS (Editors). Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. Springer, 2012.

For more publications, please see the PubMed listing.  

Research Description

Dr. Doruk Erkan has been involved in Antiphospholipid Syndrome (APS) research since 1997. His research interest includes identification of factors that increase the risk of blood clots and potential prevention strategies. He is the principal investigator in multiple clinical trials ranging from mechanistic studies to drug trials for difficult-to-treat APS patients. He has been a member of multiple APS-related national/international committees as well as an invited speaker at numerous conferences. He is the Executive Committee Chair of the newly formed international APS research network, APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking). More information about this network can be found at http://www.apsaction.org/.

Dr. Erkan is also Clinical Co-Director of the HSS Mary Kirkland Center for Lupus Care, HSS Clinical Director for the multi-site Lupus Clinical Trials Consortium, and is involved in multi-center pharmaceutical-sponsored clinical trials investigating new treatments for lupus patients, as well as their registry for lupus patients.

If you are interested in participating in an APS or Lupus clinical research study, or if you have a question about research studies, please contact Joann Vega, CCRC at 212.774.2795 or vegaj@hss.edu.

Invited Special Lecture Presentations at the International Scientific Meetings (Selected, 2011 Only)

May 2011 – Antiphospholipid Syndrome Treatment Beyond Anticoagulation: Are We There Yet? The European League Against Rheumatism (EULAR) Scientific Annual Meeting, London, UK. 

August 2011 – Primary Thrombosis Prophylaxis in Antiphospholipid Antibody Positive Patients. ReumaRio 2011 (National Brazil Rheumatology Meeting), Rio de Janeiro, Brazil.

August 2011 – Antiphospholipid Syndrome Management Beyond Anticoagulation. Are We There Yet? ReumaRio 2011 (National Brazil Rheumatology Meeting), Rio de Janeiro, Brazil.

October 2011 – Management of Antiphospholipid Syndrome.12th National Turkish Rheumatology Meeting, Antalya, Turkey.

November 2011 – APS ACTION. APS Study Group, American College of Rheumatology 75th Annual Scientific Meeting, Chicago, IL.

November 2011 – Clinical Symposium: Management of Antiphospholipid Syndrome, From Controversies to Consensus, Primary Thromboprophylaxis. American College of Rheumatology 75th Annual Scientific Meeting, Chicago, IL.

Clinical Trials

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2)
• Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
• Cognitive Dysfunction, Diffusion Tensor Imaging and Functional Magnetic Resonance Imaging (MRI) in Antiphospholipid Antibody (aPL)-negative Systemic Lupus Erythematosus (SLE) versus aPL-positive non-SLE Patients
• Autoimmune Disease Registry and Repository
• Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients with and without Systemic Lupus Erythematosus
• RITAPS: A Pilot Study Of Rituximab For The Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome (APS)

 

PATIENT FORMS:

• Welcome Letter and Directions
• New Patient Health Questionnaire - Section I (all patients)
• New Patient Health Questionnaire - Section II (only for antiphospholipid antibody positive patients)
• Established Patient Multi-Dimensional Health Assessment Questionnaire (MDHAQ)

ONGOING CLINICAL RESEARCH-RELATED WEBSITES:

• APS Action
• Illuminate